<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722603</url>
  </required_header>
  <id_info>
    <org_study_id>GABA-1</org_study_id>
    <nct_id>NCT02722603</nct_id>
  </id_info>
  <brief_title>Study to Compare Gabapentin to Tramadol in Children</brief_title>
  <official_title>Randomized, Double-blind, Double-dummy, Active Controlled, Multicentre, Non-inferiority Phase-III Study to Compare Gabapentin Liquid Formulation to Tramadol in Children Experiencing Moderate to Severe Chronic Neuropathic or Mixed Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaceutical Research Management srl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmaceutical Research Management srl</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of gabapentin relative to tramadol for the
      treatment of chronic, neuropathic or mixed pain in the paediatric population. Children from 3
      months to less than 18 years of age experiencing moderate to severe chronic pain will receive
      either gabapentin or tramadol for 15 weeks. The difference in average pain scores between
      treatment arms at the end of the treatment period will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gabapentin is indicated for the treatment of peripheral neuropathic pain in adults. In the
      absence of specific paediatric studies, it is not approved for the same condition in
      children.

      The paediatric use of gabapentin is hampered by a) the lack of a suitable paediatric
      formulation, b) the significant variability of gabapentin pharmacokinetics profile and c)
      efficacy and safety data in this specific population.

      The GABA-1 study is designed to demonstrate the efficacy of gabapentin oral solution relative
      to tramadol and to document the Pharmacokinetic and safety profile of gabapentin in this
      indication.

      GABA-1 is a non-inferiority trial because gabapentin is expected to be equally effective but
      better tolerated than tramadol, thus providing a clinical benefit to affected children.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average pain score, assessed by age-appropriate pain scales.</measure>
    <time_frame>15 weeks drug treatment</time_frame>
    <description>Pain level will be measured at baseline (before starting drug therapy) and after 15 weeks of drug treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>gabapentin / placebo tramadol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gabapentin 75 mg/ml syrup / placebo tramadol, 3 times/day for 15 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tramadol / placebo gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tramadol oral drops 100 mg/ml / placebo gabapentin, 3 times/day for 15 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gabapentin</intervention_name>
    <description>75 mg/ml gabapentin syrup</description>
    <arm_group_label>gabapentin / placebo tramadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tramadol</intervention_name>
    <description>100 mg/ml tramadol oral drops</description>
    <arm_group_label>tramadol / placebo gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo tramadol</intervention_name>
    <description>placebo tramadol oral drops</description>
    <arm_group_label>gabapentin / placebo tramadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo gabapentin</intervention_name>
    <description>placebo gabapentin syrup</description>
    <arm_group_label>tramadol / placebo gabapentin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects with neuropathic or mixed chronic pain

          -  subjects with at least moderate pain (pain intensity of ≥4/10 assessed by
             age-appropriate pain scale)

          -  subjects with stable underlying disease condition and treatment.

        Exclusion Criteria:

          -  pain duration of more than 5 years

          -  current use of gabapentin or tramadol

          -  history of failure to respond to adequate treatment by gabapentin or tramadol/opioids
             for neuropathic pain.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florentia Kaguelidou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center of Clinical Investigations, INSERM CIC 1426, Hopital Robert Debré, Assistance Publique Hopitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donato Bonifazi</last_name>
    <phone>00393287919866</phone>
    <email>donatobonifazi@pharmsrl.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qendra Spitalore Universitare Nene Tereza, Tirana</name>
      <address>
        <city>Tirana</city>
        <country>Albania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sihtasutus Tartu Uelikooli Kliinikum</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Assistance Publique-Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux De Paris - Hôpital Necker de Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux De Paris - Hôpital Robert Debré de Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaets klinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Geniko Nosokomeio Paidon Αthinon I Agia Sophia - Paidon Pentelis</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Universitair Medisch Centrum Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht, Wilhelmina Kinderziekenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.pediatricpain.eu</url>
    <description>GAPP (GAbapentin in Pediatric Pain) Consortium funded by the European Commission</description>
  </link>
  <link>
    <url>http://www.pharmsrl.com/</url>
    <description>Sponsor</description>
  </link>
  <reference>
    <citation>Finnerup NB, Sindrup SH, Jensen TS. Recent advances in pharmacological treatment of neuropathic pain. F1000 Med Rep. 2010 Jul 14;2:52. doi: 10.3410/M2-52.</citation>
    <PMID>21170362</PMID>
  </reference>
  <reference>
    <citation>Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain. 2001 Dec;17(4):284-95. Review.</citation>
    <PMID>11783808</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2016</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

